Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies
暂无分享,去创建一个
[1] G. Linette,et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. , 2016, The Lancet. Oncology.
[2] L. Nardo,et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.
[3] J. Lunceford,et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.
[4] C. Horak,et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. , 2016, The Lancet. Oncology.
[5] M. Postow,et al. Irradiation and immunotherapy: From concept to the clinic , 2016, Cancer.
[6] D. Nuyten,et al. First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results. , 2016 .
[7] K. Harrington,et al. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. , 2016 .
[8] D. Sargent,et al. Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. , 2016 .
[9] D. Schadendorf,et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). , 2016 .
[10] J. Wolchok,et al. Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP). , 2016 .
[11] E. Schmidt,et al. Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors. , 2016 .
[12] R. Sullivan,et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.
[13] J. McQuade,et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.
[14] Zhaoqin Huang,et al. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. , 2015, Cancer treatment reviews.
[15] J. Galon,et al. Immunoscore® as a predictor of response to chemotherapy in stage II and stage III colon cancer , 2015, Journal of Immunotherapy for Cancer.
[16] David C. Smith,et al. Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers , 2015, Journal of Immunotherapy for Cancer.
[17] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[18] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[19] S. Turley,et al. Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.
[20] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[21] Xiaoling Zhang,et al. Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.
[22] A. Aplin,et al. RAC1 P29S regulates PD‐L1 expression in melanoma , 2015, Pigment cell & melanoma research.
[23] J. Wolchok,et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[25] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[26] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[27] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[28] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[29] Axel Hoos,et al. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab , 2015, Pigment cell & melanoma research.
[30] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[31] Antoni Ribas,et al. Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.
[32] G. Linette,et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. , 2015 .
[33] L. Chow,et al. Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies. , 2015 .
[34] D. Schadendorf,et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. , 2015 .
[35] P. Nghiem,et al. A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma. , 2015 .
[36] J. Norton,et al. A phase I study of MEDI6383, an OX40 agonist, in adult patients with select advanced solid tumors. , 2015 .
[37] E. Plimack,et al. Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). , 2015 .
[38] P. Ascierto,et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. , 2015 .
[39] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[40] G. Salles,et al. A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL). , 2015 .
[41] T. Yau,et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[43] A. Salama,et al. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis , 2015, Journal of Immunotherapy for Cancer.
[44] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[45] Joe-Marc Chauvin,et al. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. , 2015, The Journal of clinical investigation.
[46] J. Madore,et al. PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials , 2015, Pigment cell & melanoma research.
[47] P. Ascierto,et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.
[48] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[49] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[50] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[51] Narasimhan P. Agaram,et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. , 2015, Human pathology.
[52] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[53] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] J. Wolchok,et al. Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo , 2015, The Journal of Immunology.
[55] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[56] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[57] C. Horak,et al. Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma , 2014, Clinical Cancer Research.
[58] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[59] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[60] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[61] J. Kirkwood,et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. , 2014, JAMA.
[62] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[63] J. Wolchok,et al. Ipilimumab in patients with melanoma and autoimmune disease , 2014, Journal of Immunotherapy for Cancer.
[64] Antoni Ribas,et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.
[65] L. Meng,et al. PD‐1 regulates extrathymic regulatory T‐cell differentiation , 2014, European journal of immunology.
[66] Bruce D Cheson,et al. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors , 2014, Journal of Hematology & Oncology.
[67] Antoni Ribas,et al. Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.
[68] N. Segal,et al. A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors. , 2014 .
[69] N. Rizvi,et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. , 2014 .
[70] I. Flinn,et al. Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. , 2014 .
[71] C. Rolfo,et al. A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies. , 2014 .
[72] Antoni Ribas,et al. Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma , 2014, Clinical Cancer Research.
[73] A. D. Van den Abbeele,et al. Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.
[74] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[75] R. Schreiber,et al. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.
[76] J. Wolchok,et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. , 2014, Endocrine-related cancer.
[77] Vamsidhar Velcheti,et al. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas , 2014, Clinical Cancer Research.
[78] Ryan Emerson,et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.
[79] H. Koblish,et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.
[80] Hong Wang,et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. , 2013, Cancer research.
[81] L. Gordon,et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] C. Horak,et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] Jason B. Williams,et al. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.
[84] J. Wolchok,et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.
[85] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[86] J. Taube,et al. PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival , 2013, Cancer Immunology Research.
[87] A. Korman,et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. , 2013 .
[88] F. Marincola,et al. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment , 2013, Journal of Translational Medicine.
[89] A. Hauschild,et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[91] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[92] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[93] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[94] F. Marincola,et al. The immune score as a new possible approach for the classification of cancer , 2012, Journal of Translational Medicine.
[95] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[96] E. Wherry. T cell exhaustion , 2011, Nature Immunology.
[97] G. Anderson,et al. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.
[98] R. Schreiber,et al. Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.
[99] S. Antonia,et al. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors , 2010, Cancer biology & therapy.
[100] A. Korman,et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. , 2010, Seminars in oncology.
[101] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[102] N. Munshi,et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma , 2010, Haematologica.
[103] Loise M. Francisco,et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells , 2009, The Journal of experimental medicine.
[104] B. Escudier,et al. A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma , 2009, Clinical Cancer Research.
[105] Nancy Whiting,et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[106] T. Whiteside,et al. Spontaneous apoptosis of tumor‐specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer , 2009, Head & neck.
[107] J. Bluestone,et al. Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways , 2008, Immunological reviews.
[108] J. Kirkwood,et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) , 2008 .
[109] K. Flaherty,et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] A. Lanfranco,et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.
[111] Tasuku Honjo,et al. PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.
[112] R. Herbst,et al. Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.
[113] Mark S. Anderson,et al. Brief Definitive Report , 2022 .